ABSTRACT
BACKGROUND: Apolipoprotein B (APOB) is an integral component of the chylomicron and the atherogenic lipoproteins LDL and Lp(a). Exon 26 of the APOB pre-mRNA is unusually long at 7,572 nt and is constitutively spliced. It is also subject to RNA editing in the intestine, which generates a shortened isoform, APOB48, assembled exclusively into chylomicrons. Due to its length, exon 26 contains multiple pseudo splice sites which are not spliced, but which conform to the degenerate splice site consensus. RESULTS: We demonstrate that these pseudo splice sites are repressed by multiple, tandem splicing silencers distributed along the length of exon 26. The distribution of these elements appears to be heterogeneous, with a greater frequency in the middle 4,800 nt of the exon. CONCLUSION: Repression of these splice sites is key to maintaining the integrity of exon 26 during RNA splicing and therefore the correct expression of both isoforms of APOB.
Subject(s)
Alternative Splicing , Apolipoproteins B/genetics , Down-Regulation , Silencer Elements, Transcriptional , Apolipoproteins B/chemistry , Apolipoproteins B/metabolism , Base Sequence , Exons , Humans , Molecular Sequence Data , RNA Splice SitesABSTRACT
The identification and hit-to-lead exploration of a novel, potent and selective series of histamine H(4) receptor inverse agonists is described. The initial hit, 3A (IC(50) 19 nM) was identified by means of a ligand-based virtual screening approach. Subsequent medicinal chemistry exploration yielded 18I which possessed increased potency (R-enantiomer IC(50) 1 nM) as well as enhanced microsomal stability.
Subject(s)
Histamine Antagonists/pharmacology , Receptors, G-Protein-Coupled/antagonists & inhibitors , Animals , Biological Availability , Drug Discovery , Histamine Antagonists/chemistry , Histamine Antagonists/pharmacokinetics , Inhibitory Concentration 50 , Macaca fascicularis , Rats , Receptors, Histamine , Receptors, Histamine H4 , StereoisomerismABSTRACT
A number of indole-3-glyoxylamides have previously been reported as tubulin polymerization inhibitors, although none has yet been successfully developed clinically. We report here a new series of related compounds, modified according to a strategy of reducing aromatic ring count and introducing a greater degree of saturation, which retain potent tubulin polymerization activity but with a distinct SAR from previously documented libraries. A subset of active compounds from the reported series is shown to interact with tubulin at the colchicine binding site, disrupt the cellular microtubule network, and exert a cytotoxic effect against multiple cancer cell lines. Two compounds demonstrated significant tumor growth inhibition in a mouse xenograft model of head and neck cancer, a type of the disease which often proves resistant to chemotherapy, supporting further development of the current series as potential new therapeutics.
Subject(s)
Antineoplastic Agents/chemistry , Antineoplastic Agents/therapeutic use , Head and Neck Neoplasms/drug therapy , Indoles/chemistry , Indoles/therapeutic use , Tubulin Modulators/chemistry , Tubulin Modulators/therapeutic use , Animals , Antineoplastic Agents/pharmacokinetics , Caco-2 Cells , Cell Proliferation/drug effects , Drug Screening Assays, Antitumor , Head and Neck Neoplasms/metabolism , Head and Neck Neoplasms/pathology , Heterografts , Humans , Indoles/pharmacokinetics , Male , Mice , Mice, Nude , Microtubules/drug effects , Microtubules/metabolism , Microtubules/pathology , Neoplasm Transplantation , Structure-Activity Relationship , Tubulin/metabolism , Tubulin/ultrastructure , Tubulin Modulators/pharmacokineticsABSTRACT
Melanin-concentrating hormone (MCH) has been known to be an appetite-stimulating peptide for a number of years. However, it is only recently that MCH has been discovered to be the natural ligand for a previously "orphan" G-protein-coupled receptor, now designated MCH-1R. This receptor has been shown to mediate the effects of MCH on appetite and body weight, and consequently, drug discovery programs have begun to exploit this information in the search for MCH-1R antagonists for the treatment of obesity. In this paper, we report the rapid discovery of multiple, structurally distinct series of MCH-1R antagonists using a variety of virtual screening techniques. The most potent of these compounds (12) demonstrated an IC(50) value of 55 nM in the primary screen and exhibited antagonist properties in a functional cellular assay measuring Ca(2+) release. More potent compounds were identified by follow-up searches around the initial hit. A proposed binding mode for compound 12 in a homology model of the MCH-1R is also presented.
Subject(s)
Piperazines/chemistry , Quinolines/chemistry , Receptors, Somatostatin/antagonists & inhibitors , Amino Acid Sequence , Animals , CHO Cells , Calcium/metabolism , Cricetinae , Databases, Factual , Humans , Models, Molecular , Molecular Sequence Data , Piperazines/pharmacology , Quinolines/pharmacology , Receptors, Somatostatin/chemistry , Receptors, Somatostatin/metabolism , Structure-Activity RelationshipABSTRACT
Leptin is the 167 amino-acid protein product of the Lep (obese) gene that is released predominantly from adipose tissue and circulates at levels related to the amount of fat. Leptin expression is hormonally regulated: insulin and glucocorticoids are stimulators, while inhibitors include beta-adrenergic agonists and testosterone. Recently, adenylate cyclase-coupled melanocortin receptors have been identified in murine adipose tissue, the 3T3-L1 adipocyte cell line, and in human fat tissue. These studies prompted us to evaluate the effects of pro-opiomelanocortin (POMC)-derived peptides on leptin production and expression in 3T3-L1 adipocytes in culture. 3T3-L1 pre-adipocytes differentiated by the insulin/indomethacin (I/I) method produced leptin at levels that were two times higher than those obtained in cells differentiated by the more traditional insulin/dexamethasone/isobutylmethylxanthine (I/D/M) method. By RT-PCR studies, 3T3-L1 cells expressed both the melanocortin 2 receptors (MC2-R) and melanocortin 5 receptors (MC5-R) isoforms of the melanocortin receptor at an early stage of differentiation. When I/I differentiated 3T3-L1 adipocytes were incubated with different concentrations of dibutyryl cAMP (db-cAMP) or POMC-derived peptides (ACTH and alpha-MSH), ACTH and alpha-MSH stimulated cAMP production after 30 min (2-fold increase) associated with a dose-dependent inhibition of leptin secretion (ACTHz.Gt;alpha-MSH; IC(50)=3.2+/-0.4 SE and 36+/-5 nM, respectively), maximal after 3 h of incubation (30% inhibition). In addition, 100 nM ACTH and alpha-MSH induced a 60% reduction in leptin expression by RT-PCR. Incubation of cells with 0.5 mM db-cAMP led to a more prominent inhibition of leptin expression and secretion (up to 80% at 1 and 24 h, respectively). The ACTH and alpha-MSH inhibitory effects on leptin secretion were mediated by activation of the MC2-R and MC5-R and were reversed by the MC-R antagonists ACTH(11-24) and ACTH(7-38). In summary, we have shown that POMC-peptides are potent inhibitors of leptin expression and production in 3T3-L1 adipocytes. The finding of ACTH/alpha-MSH receptor-induced inhibition of leptin production and expression in adipocytes support the possibility that there is a control mechanism for modulation of adipose tissue function via a melanocortin-leptin axis.
Subject(s)
Adipocytes/metabolism , Adrenocorticotropic Hormone/pharmacology , Leptin/metabolism , alpha-MSH/pharmacology , 3T3-L1 Cells , Animals , Cell Line , Cell Lineage , Cyclic AMP/metabolism , Dose-Response Relationship, Drug , Gene Expression Regulation , Glycerol-3-Phosphate Dehydrogenase (NAD+) , Glycerolphosphate Dehydrogenase/metabolism , Humans , Leptin/biosynthesis , Leptin/genetics , Mice , Models, Biological , Peptide Fragments/metabolism , Pro-Opiomelanocortin/metabolism , Receptor, Melanocortin, Type 1/antagonists & inhibitors , Receptor, Melanocortin, Type 1/metabolism , Receptors, LeptinABSTRACT
We made psychiatric and intellectual assessments of 140 children with attention deficit hyperactivity disorder (ADHD), 120 normal controls, and their 303 siblings. The index children were white, non-Hispanic boys. ADHD children were more likely to have had learning disabilities, repeated grades, been placed in special classes, and received academic tutoring. They also did worse on the Wechsler Intelligence Scale for Children--Revised (WISC-R). Among ADHD probands, comorbid conduct, major depressive, and anxiety disorders predicted school placement more than school failure or WISC-R scores. However, the neuropsychological disability of all ADHD children could not be attributed to comorbid disorders because those without comorbidity had more school failure and lower WISC-R scores than normal controls. Intellectual impairment was also increased among siblings of ADHD children. This provides converging evidence that the ADHD syndrome is familial.
Subject(s)
Attention Deficit Disorder with Hyperactivity/genetics , Intelligence , Learning Disabilities/genetics , Adolescent , Attention Deficit Disorder with Hyperactivity/psychology , Child , Education, Special , Humans , Learning Disabilities/psychology , Male , Risk Factors , Underachievement , Wechsler ScalesABSTRACT
Since the 1940s, American Indians (AIs) have increasingly urbanized, moving off of reservations in large part due to federal policies of tribal termination and relocation. Though previous AI research has largely focused on reservation-associated challenges, many of these same challenges persist among urban AI populations. One mutual concern is the growing prevalence and incidence of type II diabetes mellitus (T2DM). While behavioral, genetic, and socioeconomic determinants of T2DM have been explored, much less is known about the influence of cultural and psychosocial factors. Recent studies suggest that the way AIs perceive diabetes may affect their health trajectory and explain their poor prognosis. Through the use of the Illness Perception Questionnaire, we explored this hypothesis in a pilot study of urban AI with T2DM living in Los Angeles County. We found that the majority of participants have a neutral perception about their diabetes: They view their condition to be long lasting yet treatable and indicate reasonable understanding of its symptoms and progression. We also identified "personal control," the level of perceived control one has over his or her disease, as a strong correlate of overall illness perception and, thus, a potentially useful psychological metric.
Subject(s)
Diabetes Mellitus, Type 2/ethnology , Health Knowledge, Attitudes, Practice/ethnology , Indians, North American/ethnology , Adult , Female , Humans , Male , Middle Aged , Urban PopulationABSTRACT
We have modified the previously reported 2-aminoquinoline 1 to provide two novel series of MCH-1R antagonists. Representative compounds from the quinazoline and benzimidazole series have been shown to be potent and selective, with promising in vitro eADME profiles.
Subject(s)
Benzimidazoles/chemical synthesis , Quinazolines/chemical synthesis , Receptors, Somatostatin/antagonists & inhibitors , Benzimidazoles/pharmacology , Humans , Inhibitory Concentration 50 , Protein Binding , Quinazolines/pharmacology , Structure-Activity RelationshipABSTRACT
A new series of 2-aminoquinolines has been identified as antagonists of the melanin concentrating hormone receptor (MCH-1R). Syntheses and structure-activity relationships are described leading to a compound having low nanomolar activity against the receptor and demonstrating functional antagonism. Studies also showed that some of the compounds were selective against a range of other G protein-coupled receptors.